Healthcare Active Movers: Zogenix, Inc. (NASDAQ:ZGNX), Orexigen Therapeutics (NASDAQ:OREX), Merck & Co (NYSE:MRK), Boston Scientific Corporation (NYSE:BSX), Bristol-Myers Squibb (NYSE:BMY)



Zogenix, Inc (NASDAQ:ZGNX) CEO Roger Hawley unloaded 25,078 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $2.10, for a total transaction of $52,663.80. Following the completion of the sale, the chief executive officer now directly owns 1,204,447 shares in the company, valued at approximately $2,529,339. Zogenix, Inc. (NASDAQ:ZGNX) stock performance was -0.54% in last session and finished the day at $1.84. Traded volume was 5.05million shares in the last session and the average volume of the stock remained 3.04million shares. The beta of the stock remained 2.12. Zogenix, Inc. (NASDAQ:ZGNX) insider ownership is 0.90%.

The FDA will decide on Wednesday whether to approve a new weight loss drug, Contrave, from Orexigen Therapeutics Inc. (NASDAQ:OREX), a smallish biotech company with a market cap of just $760 million. Orexigen Therapeutics, Inc. (NASDAQ:OREX) rose 3.07 percent to $6.71 Monday on volume of 6.52million shares. The intra-day range of the stock was $6.51 to $6.78. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has a market capitalization of $780.56million.

Merck & Co. Inc. (NYSE:MRK) made an official statement, revealing that it reached an agreement for the acquisition of Idenix Pharmaceuticals Inc. in a deal that is estimated to 3.85 billion dollars. The purchase will help the company to broaden its experimental pipeline for hepatitis C treatments. Merck & Co., Inc. (NYSE:MRK)’s stock on June 09, 2014 reported a increase of 0.16% to the closing price of $57.94. Its fifty two weeks range is $44.62 -$59.84. The total market capitalization recorded $169.74billion. The overall volume in the last trading session was 8.08million shares. In its share capital, MRK has 2.92billion outstanding shares.

Boston Scientific Corporation (NYSE:BSX) has launched the RESPOND Post Market Registry to evaluate the real world performance of the Lotus Valve System – a differentiated second generation transcatheter aortic valve implantation (:TAVI) technology. On Monday, shares of Boston Scientific Corporation (NYSE:BSX) dropped -2.82% to close the day at $12.76. Company return on investment (ROI) is 2.10% and its monthly performance is recorded as -0.31%. Boston Scientific Corporation (NYSE:BSX) quarterly revenue growth is -5.20%.

Bristol-Myers Squibb Co. (NYSE:BMY) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most “interesting” ideas that merit further research by investors. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -1.40% in last session and finished the day at $46.59. Traded volume was 11.93million shares in the last session and the average volume of the stock remained 8.82million shares. The beta of the stock remained 0.48. Bristol-Myers Squibb Co (NYSE:BMY) insider ownership is 0.10%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone